This Is MS Multiple Sclerosis Community: Knowledge & Support

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.
It is currently Sat May 25, 2013 1:50 pm


All times are UTC - 8 hours [ DST ]




Post new topic Reply to topic  [ 1 post ] 
Author Message
 Post subject: Interleukin-1
PostPosted: Fri Oct 26, 2007 7:35 am 
Offline
Family Elder
User avatar

Joined: Fri Mar 25, 2005 4:00 pm
Posts: 599
Location: Northamptonshire, England.
Whenever injury occurs to brain tissue inflammation occurs in response, (and "injury" can include neurodegeneration – neurons dying due to some other cause), IL – 1 is activated and appears to prolong and enhance the inflammation to the point where it becomes damaging. Inhibiting it using IL – 1 RA might be a way to minimize the damage:

Biochem Soc Trans. 2007 Oct;35(Pt 5):1122-6
Authors: Simi A, Tsakiri N, Wang P, Rothwell NJ
Inflammation occurs rapidly in response to acute brain insults such as stroke, haemorrhage or trauma, and can be sustained for long periods of time, for example in Alzheimer's or Parkinson's diseases and multiple sclerosis. Experimental evidence indicates that inflammation plays a major role in neurodegeneration under these conditions, and that the cytokine IL-1 (interleukin-1) is a pivotal mediator. IL-1 is expressed rapidly in response to neuronal injury, predominantly by microglia, and elevated levels of endogenous or exogenous IL-1 markedly exacerbate injury. The naturally occurring IL-1RA (IL-1 receptor antagonist) markedly inhibits ischaemic, excitotoxic and traumatic brain injury in rodents, and has shown promise in a Phase II clinical trial in stroke patients. The mechanisms of IL-1 expression, release and action in neurodegeneration are not fully elucidated and appear multiple. Systemic IL-1 markedly enhances ischaemic brain injury via release of neutrophils into circulation, neutrophil adhesion to injured cerebrovasculature and CNS (central nervous system) invasion, and cell death via activation of matrix metalloproteinase-9. IL-1 also influences the release of toxins from glial and endothelial cells. Neuronal responses to excitotoxins and physiological factors may have an impact on neuronal survival. IL-1RA, delivered peripherally, can enter the CNS in animals and humans and has no adverse effects in stroke or subarachnoid haemorrhage patients, but shows potential benefit in acute stroke patients.
PMID: 17956293 [PubMed - in process

_________________
Dom


Top
 Profile  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 1 post ] 

All times are UTC - 8 hours [ DST ]


Related topics
 Topics   Author   Replies   Views   Last post 
There are no new unread posts for this topic. interleukin-21

dignan

0

751

Sat Jun 13, 2009 10:52 am

dignan View the latest post

There are no new unread posts for this topic. Interleukin 17 and 27 Study

Dunmann

0

799

Wed Aug 16, 2006 7:33 am

Dunmann View the latest post

There are no new unread posts for this topic. Is targeting Interleukin 17 the right direction?

GFPRIME

1

264

Mon Jun 11, 2012 5:34 pm

lyndacarol View the latest post

 


Who is online

Users browsing this forum: No registered users


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum

Search for:
Jump to: